IRIDEX Corporation (NASDAQ:IRIX) Shares Shorted: Short Interest Down 48.3% in October

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) was the target of a large decrease in short interest in the month of October. As of October 30th, there was short interest totaling 39,421 shares, a decrease of 48.3% from the October 15th total of 76,195 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 24,978 shares, the short-interest ratio is currently 1.6 days.

Institutional Investors Weigh In On IRIDEX

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC raised its holdings in shares of IRIDEX by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after buying an additional 25,067 shares in the last quarter. Weber Capital Management LLC ADV bought a new position in shares of IRIDEX in the 2nd quarter worth $206,616. United Capital Financial Advisors LLC purchased a new position in IRIDEX during the 2nd quarter worth $41,000. Diversify Wealth Management LLC bought a new position in IRIDEX in the 1st quarter valued at $35,000. Finally, Diversify Advisory Services LLC purchased a new position in shares of IRIDEX during the 2nd quarter valued at $30,000. 20.10% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, IRIDEX currently has a consensus rating of “Hold” and a consensus price target of $3.00.

View Our Latest Analysis on IRIDEX

IRIDEX Trading Up 1.7%

IRIDEX stock traded up $0.01 during trading hours on Tuesday, reaching $0.70. 171,774 shares of the company were exchanged, compared to its average volume of 215,998. The stock has a 50-day moving average of $0.71 and a 200 day moving average of $1.00. The firm has a market cap of $12.29 million, a price-to-earnings ratio of -3.50 and a beta of 0.64. IRIDEX has a 12 month low of $0.61 and a 12 month high of $1.65.

IRIDEX (NASDAQ:IRIX – Get Free Report) last issued its earnings results on Tuesday, November 17th. The medical equipment provider reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.04). The firm had revenue of $10.16 million for the quarter, compared to the consensus estimate of $12.64 million. As a group, research analysts forecast that IRIDEX will post -0.12 EPS for the current year.

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation develops, manufactures and markets laser-based medical systems and related delivery devices for eye-care professionals. Its products are used to treat retinal diseases and glaucoma, including through laser procedures designed to preserve or improve vision. The company’s offerings include ophthalmic laser systems such as the Cyclo G6 glaucoma laser system and IQ-series photocoagulators, along with treatment-delivery devices and technologies including MicroPulse laser therapy. IRIDEX was founded in 1989 and serves customers internationally through direct sales and distribution partners.

See Also

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.